CHMP rec­om­mends re­ject­ing Amy­lyx ALS drug, pit­ting EMA against FDA and Health Cana­da

2 years ago
FDA+

Elu­ci­da On­col­o­gy nabs more funds for its take on AD­Cs, sees po­ten­tial in ra­dio­ther­a­py part­ner­ship

2 years ago
Financing
Startups

Se­bas­t­ian Guth sharp­ens his fo­cus at Bay­er; As CD47 strug­gles per­sist, I-Mab ap­points CEO

2 years ago
Peer Review

Apogee files to go pub­lic, un­veil­ing plans to make a play for Dupix­en­t's turf

2 years ago
Financing
Startups

CAR-T cell ther­a­py for myas­the­nia gravis shows promise in small study by Carte­sian Ther­a­peu­tics

2 years ago
R&D
Cell/Gene Tx

In­ter­cep­t's NASH drug is again re­ject­ed by FDA, lead­ing the com­pa­ny to re­struc­ture in piv­ot from dis­ease

2 years ago
Pharma
FDA+

MPP signs on four gener­ics mak­ers to make No­var­tis' Tasigna more ac­ces­si­ble

2 years ago
Deals
Pharma

Eli Lil­ly and di­a­betes as­so­ci­a­tion team up with MLB play­er to pro­mote its in­sulin cost cap

2 years ago
Pharma
Marketing

EMA asks for more in­for­ma­tion af­ter safe­ty sig­nal aris­es for GLP-1s, semaglu­tide in thy­roid can­cer

2 years ago
Pharma

Ab­b­Vie spurs em­ploy­ee gen­eros­i­ty with week­long vol­un­teer­ing ini­tia­tive

2 years ago
Pharma
Marketing

Roche stops de­vel­op­ment on an An­gel­man ther­a­py due to dis­ap­point­ing ef­fi­ca­cy, says it’s seek­ing ex­ter­nal part­ner

2 years ago
R&D
Pharma

As­traZeneca, Sanofi turn to Al­pha­bet spin­out's AI and quan­tum tech­nolo­gies for drug dis­cov­ery

2 years ago
Deals

Up­dat­ed: FDA ap­proves Sarep­ta’s Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py via ac­cel­er­at­ed path­way

2 years ago
Pharma
Cell/Gene Tx

US gov­ern­ment chal­lenges ju­ry de­ci­sion in Gilead HIV patent tri­al

3 years ago
Pharma
Law

Man­u­fac­tur­ing roundup: An­de­lyn Bio­sciences opens new fa­cil­i­ty in Ohio; No­vo warns of Ozem­pic coun­ter­feit

3 years ago
Manufacturing

Ra­dioiso­tope man­u­fac­tur­er North­Star Med­ical Tech­nolo­gies names new CEO

3 years ago
People
Manufacturing

Two biotechs launch pub­lic of­fer­ings; Vaxxin­i­ty shares safe­ty da­ta on its Parkin­son's vac­cine

3 years ago
News Briefing

Cor­rect­ed: Prime Med­i­cine part­ners with Ver­sant-backed biotech to de­vel­op safer stem cell trans­plants

3 years ago
Deals
Cell/Gene Tx

Aslan out­li­cens­es atopic der­mati­tis an­ti­body in $138.5M deal

3 years ago
Deals
R&D

Ae­glea Bio­Ther­a­peu­tics ac­quires start­up Spyre in bid to go af­ter Mer­ck’s Prometheus, Roivant’s Tela­vant

3 years ago
Financing
Startups

Tour­ma­line Bio re­verse merges in­to Ta­laris and rais­es funds to tar­get thy­roid eye dis­ease and phar­ma ri­vals

3 years ago
Financing
Startups

‘The sleep­ing gi­ant is wak­ing up’: FTC rais­es the pres­sure on phar­ma deal­mak­ing

3 years ago
Deals
Pharma

Sarep­ta's gene ther­a­py for Duchenne ex­pect­ed to get FDA rul­ing to­day

3 years ago
Cell/Gene Tx
FDA+

As Roivant read­ies for a UC clash with Mer­ck, CEO Matt Gline is can­did about keep­ing a com­pet­i­tive edge

3 years ago
R&D
First page Previous page 322323324325326327328 Next page Last page
A service from the Financial Times